Long-term effect of AIDS infected individuals with hepatitis B virus infection on abnormal liver enzymes in Guangzhou

CHEN Mingyu; LIU Cong; TANG Xiaoping; LI Quanmin; LI Linghua; GU Jing; CAI Weiping

doi:10.16462/j.cnki.zhjbkz.2025.02.009

Volume 29 Issue 2

Feb. 2025

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2025 > 29(2): 178-185

CHEN Mingyu, LIU Cong, TANG Xiaoping, LI Quanmin, LI Linghua, GU Jing, CAI Weiping. Long-term effect of AIDS infected individuals with hepatitis B virus infection on abnormal liver enzymes in Guangzhou[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(2): 178-185. doi: 10.16462/j.cnki.zhjbkz.2025.02.009

Citation:

CHEN Mingyu, LIU Cong, TANG Xiaoping, LI Quanmin, LI Linghua, GU Jing, CAI Weiping. Long-term effect of AIDS infected individuals with hepatitis B virus infection on abnormal liver enzymes in Guangzhou[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(2): 178-185. doi: 10.16462/j.cnki.zhjbkz.2025.02.009

Citation:

CHEN Mingyu, LIU Cong, TANG Xiaoping, LI Quanmin, LI Linghua, GU Jing, CAI Weiping. Long-term effect of AIDS infected individuals with hepatitis B virus infection on abnormal liver enzymes in Guangzhou[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(2): 178-185. doi: 10.16462/j.cnki.zhjbkz.2025.02.009

PDF( 1757 KB)

Long-term effect of AIDS infected individuals with hepatitis B virus infection on abnormal liver enzymes in Guangzhou

doi: 10.16462/j.cnki.zhjbkz.2025.02.009

1.
Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou 510000, China
2.
Infectious Disease Center, Guangzhou Eighth People′s Hospital, Guangzhou Medical University, Guangzhou 510000, China

Funds:

National Science and Technology Major Project of the Ministry of Science and Technology during the 13rd Five-Year Plan Period of China 2018ZX10715004

More Information

Corresponding author: LI Linghua, E-mail: llheliza@126.com; GU Jing, E-mail: gujing5@mail.sysu.edu.cn
Received Date: 2024-03-01
Rev Recd Date: 2024-12-20

Available Online: 2025-03-08

Publish Date: 2025-02-10

Abstract

Abstract

Objective To analyze the impact of concurrent HBV infection on the occurrence of liver enzyme abnormalities in HIV-infected individuals during long-term antiviral therapy in Guangzhou City. Methods A retrospective cohort study was conducted in December 2023, using follow-up data from HIV-infected individuals who received antiviral treatment at the Eighth People′s Hospital of Guangzhou from January 1 2010, to June 30 2021, as recorded in the "Comprehensive AIDS Prevention and Control Data Information Management System." The study employed a joinpoint regression model to analyze the changing trend in the risk of liver enzyme abnormalities. Propensity score matching was applied to enhance comparability between individuals co-infected with HBV and those simple HIV infections. Additionally, a multilevel logistic regression model was used to analyze the impact of concurrent HBV infection on liver enzyme abnormalities. Results After applying the inclusion and exclusion criteria, 13 829 HIV-infected individuals were screened, and following propensity score matching, a total of 9 050 HIV-infected individuals were included in the analysis. Among individuals infected with HIV alone and those with HBV, 61.8% and 70.4% experienced liver enzyme abnormalities, respectively. The risk of occurrence showed a rapid decrease within 9 months of treatment, a slow decrease from 9 to 27 months of treatment, and a stable three stage period after 27 months of treatment. For HIV-infected individuals, the co-infection with HBV within the first 9 months of antiviral treatment is a risk factor for liver enzyme abnormalities (OR=1.637, 95% CI: 1.437-1.866), but after 9 months of continuous antiviral treatment, there was no association between ca-HBV and liver enzyme abnormalities (P>0.05). Conclusions In the follow-up and management of AIDS, the liver function of patients with HBV infection should be focused on in the first year after starting antiviral treatment.
- Human immunodeficiency virus,
- Hepatitis B,
- Highly active antiretroviral therapy

FullText(HTML)

References(23)

References

[1]	中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版)[J]. 中华内科杂志, 2021, 60(12): 1106-1128. DOI: 10.3760/cma.j.cn112138-20211006-00676. Chinese Medical Association, Infectious Diseases Society, AIDS and Hepatitis C Study Group, Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2021 edition)[J]. Chin J Intern Med, 2021, 60(12): 1106-1128. DOI: 10.3760/cma.j.cn112138-20211006-00676.
[2]	Cowell A, Shenoi SV, Kyriakides TC, et al. Trends in hospital deaths among human immunodeficiency virus-infected patients during the antiretroviral therapy era, 1995 to 2011[J]. J Hosp Med, 2015, 10(9): 608-614. DOI: 10.1002/jhm.2409.
[3]	Cai J, Osikowicz M, Sebastiani G. Clinical significance of elevated liver transaminases in HIV-infected patients[J]. AIDS, 2019, 33(8): 1267-1282. DOI: 10.1097/QAD.0000000000002233.
[4]	Scherzer R, Heymsfield SB, Rimland D, et al. Association of serum albumin and aspartate transaminase with 5-year all-cause mortality in HIV/hepatitis C virus coinfection and HIV monoinfection[J]. AIDS, 2017, 31(1): 71-79. DOI: 10.1097/QAD.0000000000001278.
[5]	贾小芳, 谭智汨. 鸡尾酒疗法治疗艾滋病药物副作用的研究进展[J]. 中国生物制品学杂志, 2019, 32(8): 929-933. Jia XF, Tan ZM. Progress in research on side effect of cocktail therapy for AIDS[J]. Chin J Biol, 2019, 32(8): 929-933.
[6]	Fernández-Montero JV, Barreiro P, Vispo E, et al. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy[J]. Antivir Ther, 2014, 19(3): 287-292. DOI: 10.3851/IMP2703.
[7]	Sagir A, Glaubach B, Sahin K, et al. Transient elastography for the detection of liver damage in patients with HIV[J]. Infect Dis Ther, 2015, 4(3): 355-364. DOI: 10.1007/s40121-015-0073-y.
[8]	Benhamou Y, di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy[J]. Hepatology, 2001, 34(2): 283-287. DOI: 10.1053/jhep.2001.26517.
[9]	Zhang C, Ren Q, Chang WH. Epidemiological features and risk factors for acquiring hepatitis B, hepatitis C, and syphilis in HIV-infected patients in Shaanxi Province, Northwest China[J]. Int J Environ Res Public Health, 2020, 17(6): 1990. DOI: 10.3390/ijerph17061990.
[10]	Sarmati L, Malagnino V. HBV infection in HIV-driven immune suppression[J]. Viruses, 2019, 11(11): 1077. DOI: 10.3390/v11111077.
[11]	Copeland NK, Eller MA, Kim D, et al. Brief report: increased inflammation and liver disease in HIV/HBV-coinfected individuals[J]. J Acquir Immune Defic Syndr, 2021, 88(3): 310-313. DOI: 10.1097/QAI.0000000000002760.
[12]	Kimpiatu JP M, Mbendi CN, et al. Factors associated with liver enzyme abnormalities in hiv-hbv and/or HCV Co-infected patients in Kinshasa, democratic republic of the Congo: multicenter cross-sectional study[J]. Rambam Maimonides Med J, 2022, 13(3): e0016. DOI: 10.5041/rmmj.10474.
[13]	Sookoian S, Pirola CJ. Liver enzymes, metabolomics and genome-wide association studies: from systems biology to the personalized medicine[J]. World J Gastroenterol, 2015, 21(3): 711-725. DOI: 10.3748/wjg.v21.i3.711.
[14]	Qin FX, Jiang JJ, Qin CW, et al. Liver damage in patients living with HIV on antiretroviral treatment with normal baseline liver function and without HBV/HCV infection: an 11-year retrospective cohort study in Guangxi, China[J]. BMJ Open, 2019, 9(4): e023140. DOI: 10.1136/bmjopen-2018-023140.
[15]	Enoh JE, Cho FN, Manfo FP, et al. Abnormal levels of liver enzymes and hepatotoxicity in HIV-positive, TB, and HIV/TB-coinfected patients on treatment in fako division, southwest region of Cameroon[J]. Biomed Res Int, 2020, 2020: 9631731. DOI: 10.1155/2020/9631731.
[16]	Gowda C, Newcomb CW, Liu Q, et al. Risk of acute liver injury with antiretroviral therapy by viral hepatitis status[J]. Open Forum Infect Dis, 2017, 4(2): ofx012. DOI: 10.1093/ofid/ofx012.
[17]	Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 358-380. DOI: 10.1002/hep.29086.
[18]	Van Welzen B, Mudrikova T, Arends J, et al. No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients[J]. HIV Med, 2012, 13(7): 448-452. DOI: 10.1111/j.1468-1293.2012.00995.x.
[19]	Núñez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management[J]. J Hepatol, 2006, 44(1 Suppl): S132-S139. DOI: 10.1016/j.jhep.2005.11.027.
[20]	周路路, 刘娜, 李春霞, 等. 慢性HBV感染免疫控制期的抗病毒治疗[J]. 临床肝胆病杂志, 2020, 36(5): 1134-1137. DOI: 10.3969/j.issn.1001-5256.2020.05.041. Zhou LL, Liu N, Li CX, et al. Current status of the diagnosis and treatment of chronic hepatitis B virus infection with immune control[J]. J Clin Hepatol, 2020, 36(5): 1134-1137. DOI: 10.3969/j.issn.1001-5256.2020.05.041.
[21]	Wang T, Dai YZ, Zhang M, et al. Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with low-level HBsAg[J]. Int J Mol Med, 2018, 42(5): 2689-2699. DOI: 10.3892/ijmm.2018.3831.
[22]	Harada K, Ishinuki T, Ohashi Y, et al. Nature of the liver volume depending on the gender and age assessing volumetry from a reconstruction of the computed tomography[J]. PLoS One, 2021, 16(12): e0261094. DOI: 10.1371/journal.pone.0261094.
[23]	Talip SB, Mahmood MH, Azmi Murad AH, et al. A retrospective study on liver function tests & urine protein in presumptive non-alcoholic fatty liver cases performed in A local private laboratory service[J]. Trends Undergrad Res, 2022, 5(2): i1-8. DOI: 10.33736/tur.5118.2022.